Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

112 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2025-01-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates a new treatment combination of ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory multiple myeloma. Participants will either receive ixazomib with cyclophosphamide and dexamethasone or cyclophosphamide and dexamethasone alone.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cyclophosphamide and dexamethasone are very commonly used in the treatment of multiple myeloma and are often given with a third drug (e.g. thalidomide, lenalidomide or bortezomib). The combination of conventional and new drugs has provided benefits in both overall survival and progression free survival, however there are few treatments available for patients who have not responded well (refractory) to their previous treatment or who need further treatment because their myeloma has come back (relapsed). Thus there is a need for new agents for these patients.

The development of ixazomib provides the opportunity to increase anti-tumour activity against a wider range of tumour types. Early clinical trials data suggests it has anti-tumour activity in heavily pre-treated multiple myeloma patients with durable responses/disease control and is generally well tolerated.

Cyclophosphamide and dexamethasone are both predominantly used in treatment of multiple myeloma and for patients with relapsed or refractory multiple myelomas (RRMM), who have relapsed after bortezomib and lenalidomide. Therefore the evaluation of ixazomib in combination with cyclophosphamide and dexamethasone is the most valuable and practical option for patients.

The primary end point of this study is progression-free survival (PFS). Secondary end points include toxicity and safety.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ixazomib

Chemotherapy

Intervention Type DRUG

Cyclophosphamide

Chemotherapy

Intervention Type DRUG

Dexamethasone

Chemotherapy

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to give informed consent and willing to follow study protocol assessments
* Aged 18 years or over
* Participants with confirmed multiple myeloma based on International Myeloma Working Group (IMWG) criteria, 2009
* Measurable disease
* Participants with relapsed or relapsed refractory myeloma and now require further treatment following exposure to thalidomide, lenalidomide and bortezomib regardless of response to these
* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
* Required laboratory values within 14 days prior to Randomisation:
* Platelet count ≥50x109/L. Platelet support is permitted within 14 days prior to Randomisation
* Absolute neutrophil count ≥1.0 x 109/L
* Haemoglobin \> 9 g/dL. Blood support is permitted
* Alanine aminotransferase (ALT) and / or Aspartate aminotransferase (AST) ≤3 x upper limit of normal
* Creatinine clearance ≥ 30 ml/min (using Cockcroft Gault formula)
* Bilirubin ≤1.5 x upper limit of normal
* Both non-sterilised and sterilised females and males of reproductive age should use effective methods of contraception during the entire trial treatment (including treatment breaks) and up to 90 days after the last dose of trial treatment
* Post allograft patients may be included

Exclusion Criteria

* Those with non-measurable disease
* Those with a solitary bone or solitary extramedullary plasmacytoma
* Plasma cell leukaemia
* Prior malignancy other than those treated with curative surgery.
* Participants with a known or underlying uncontrolled concurrent illness that, in the investigators opinion, would make the administration of the study drug hazardous or circumstances that could limit compliance with the study
* Patients who have previously received MLN9708/Ixazomib in a trial. Previous experimental agents or approved anti-tumour treatment within 30 days before the date of randomisation.
* A maximum of 160mg of dexamethasone (in 40mg blocks) may be given between screening and the beginning of treatment if medically required but should be stopped before trial treatment starts. Bisphosphonates for bone disease and radiotherapy for palliative intent are also permitted
* Participants with a history of a refractory nausea, diarrhoea, vomiting, malabsorption, gastrointestinal surgery or other procedures that might, in the opinion of the Investigator, interfere with the absorption or swallowing of the study drug(s)
* Peripheral neuropathy of ≥ grade 2 severity
* Gastrointestinal disorders that may interfere with absorption of the study drug
* Active symptomatic fungal, bacterial, and/or viral infection including known active HIV or known viral (A, B or C) hepatitis
* Female patients who are lactating or have a positive serum pregnancy test during the screening period
* Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent
* Systemic treatment, within 14 days before the first dose of MLN9708, with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John's wort
* Major surgery within 14 days prior to the date of randomisation
* Radiotherapy within 14 days prior to randomisation
* Disease involving the Central Nervous System

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gordon Cook

Chief Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gordon Cook

Role: PRINCIPAL_INVESTIGATOR

Leeds Teaching Hospitals NHS Trust

Review additional registry numbers or institutional identifiers associated with this trial.

HM13/10993

Identifier Type: -

Identifier Source: org_study_id

Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Study Design

Study Groups

Ixazomib, CD

Ixazomib

Cyclophosphamide

Dexamethasone

CD

Cyclophosphamide

Dexamethasone

Interventions

Ixazomib

Cyclophosphamide

Dexamethasone

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

Myeloma UK

Millennium Pharmaceuticals, Inc.

University of Leeds

Responsible Party

Gordon Cook

Principal Investigators

Gordon Cook

Locations

Queen Elizabeth Medical Centre

Heart of England NHS Foundation Trust

Royal Bournemouth General Hospital

University Hospital Bristol NHS Foundation Trust

North Tees and Hartlepool NHS Foundation Trust

Leeds Teaching Hospitals NHS Trust

Royal Liverpool and Broadgreen University Hospital NHS Trust

Barts and the London NHS Trust

University College London Hospitals NHS Foundation Trust

Guy's and St Thomas's NHS Foundation Trust

Royal Marsden Hospital

Imperial College Healthcare NHS Trust

The Christie NHS Foundation Trust

Nottingham University Hospital NHS Trust

Churchill Hospital

Sheffield Teaching Hospitals NHS Foundation Trust

Southampton University Hospital NHS Trust

The Royal Wolverhampton Hospital NHS Trust

Countries

Other Identifiers

HM13/10993